

**AMENDMENT**

**IN THE CLAIMS**

Please cancel claims 25, 26, 29, and 42-79.

Please amend claims 3, 4, 17, 18, 30, and 36 as follows:

1. (original) A method for inhibiting cell growth or enhancing cell death comprising:
  - a) providing a photosensitive agent to a cell;
  - b) applying an electric pulse to the cell of a sufficient strength and duration to electroporate the cell with the photosensitive agent; and
  - c) applying light of an activatable wavelength to the cell thereby activating the agent and inhibiting cell growth or enhancing cell death.
2. (original) The method of claim 1, wherein multiple pulses are applied to the cell.
3. (currently amended) The method of claim 1, wherein the pulse amplitude is about ~~0.1~~ 10 kV/cm to about 6.0 kV/cm.
4. (currently amended) The method of claim 1, wherein the pulse width is about 0.1 milliseconds to about 10 milliseconds.
5. (original) The method of claim 1, wherein the pulse is applied using at least two electrodes.
6. (original) The method of claim 5, wherein at least one light conductor is combined with the electrode.
7. (original) The method of claim 6, wherein the electrode and the light conductor comprise an

electroporation catheter configuration.

8. (original) The method of claim 6, wherein the light conductor comprises a fiberoptic rod.
9. (original) The method of claim 8, wherein the fiberoptic rod comprises a plurality of optical fibers.
10. (original) The method of claim 6, wherein the electrodes comprise at least two needle electrodes.
11. (original) The method of claim 10, wherein the needle electrodes are heatable.
12. (original) The method of claim 10, wherein the needle electrodes are further extended with one or more fiberoptics comprising the light conductor.
13. (original) The method of claim 1, wherein the light is applied prior to, simultaneously with, or following the pulse.
14. (original) The method of claim 1, wherein the light is applied by a laser.
15. (original) The method of claim 1, wherein the light is applied by a tungsten lamp.
16. (original) The method of claim 1, wherein the light is applied by a near ultraviolet lamp.
17. (currently amended) The method of claim 1, wherein the light has a wavelength of about 300 nm to about 950 nm.
18. (currently amended) The method of claim 1, wherein the amount of light applied is about 50 J/cm<sup>2</sup> to about 1000J/cm<sup>2</sup>.
19. (original) The method of claim 1, wherein the light is applied extracorporeally.
20. (original) The method of claim 1, wherein the light is applied internally.
21. (original) The method of claim 20, wherein the light is applied with a fiberoptic rod.

1 October 2003

22. (original) The method of claim 21, wherein the fiberoptic rod comprises a plurality of optical fibers.
23. (original) The method of claim 1, further comprising applying heat to the cell.
24. (original) The method of claim 23, wherein the heat has a temperature of about 36° C to 42° C.
25. (canceled)
26. (canceled)
27. (original) The method of claim 1, wherein the photosensitive agent is a cytostatic agent.
28. (original) The method of claim 27, wherein the cytostatic agent is selected from the group consisting of daunomycin, adriamycin and actinomycin.
29. (canceled)
30. (currently amended) The method of claim 29, wherein the ~~sensitizing~~ photosensitive agent is 1 aevuline acid.
31. (original) The method of claim 30, wherein the photosensitive agent is protoporphyrin IX.
32. (original) The method of claim 1, wherein the method is performed in a subject.
33. (original) The method of claim 32, wherein the subject is a human.
34. (original) The method of claim 1, further comprising administering a visualizing agent to the subject.
35. (original) The method of claim 1, wherein the electrodes comprise meander electrodes.
36. (currently amended) A The method of claim 1, wherein said method is for treating a cell

proliferative disorder ~~by in a subject comprising:~~

- ~~(a) administering a the photosensitive agent to a subject having or suspected of having a cell proliferative disorder;~~
- ~~(b) applying an electric pulse to the cell in the subject of a sufficient strength and duration to electroporate the cell with the photosensitive agent; and~~
- ~~(c) applying light of a photoactivating wavelength to the cell thereby photoactivating the agent and treating the cell proliferative disorder.~~

- 37. (original) The method of claim 36, wherein the cell proliferative disorder is benign.
- 38. (original) The method of claim 36, wherein the cell proliferative disorder is a cancer.
- 39. (original) The method of claim 38, wherein the cancer is selected from the group consisting of skin cancer, a solid tumor, a metastasizing cancer and hematopoietic cancer.
- 40. (original) The method of claim 39, wherein the hematopoietic cancer is histiocytic lymphoma.
- 41. (original) The method of claim 36, wherein multiple pulses are applied to the cell.
- 42-79. (canceled)